Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428787 | 0.87 | CA12 (0.34) | — | |
| SCHEMBL4436060 | 0.82 | PTPN1 (0.34) | LMNA | |
| SCHEMBL4436063 | 0.82 | PTPN1 (0.34) | LMNA | |
| SCHEMBL11064469 | 0.80 | NAAA (0.33) | — | |
| SCHEMBL4437733 | 0.78 | PTPN1 (0.33) | LMNA | |
| SCHEMBL4428294 | 0.78 | ATM (0.38) | — | |
| SCHEMBL4428248 | 0.76 | NAAA (0.40) | — | |
| SCHEMBL4426715 | 0.74 | NAAA (0.43) | — | |
| SCHEMBL4427552 | 0.74 | NAAA (0.43) | — | |
| SCHEMBL4430261 | 0.74 | NAAA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544461-B2 | Near infrared ray activation type positive resin composition | KANSAI PAINT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7358030-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-20070259279-A1 | Near Infrared Ray Activation Type Positive Resin Composition | KANSAI PAINT CO., LTD. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1788432-A1 | POSITIVE RESIN COMPOSITION OF NEAR-INFRARED-RAY ACTIVATION TYPE | Kansai Paint Co., Ltd. (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060074262-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7015363-B2 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040181097-A1 | Process for producing ether compound | KYOWA YUKA CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1415968-A1 | PROCESS FOR PRODUCING ETHER COMPOUND | Kyowa Yuka Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074262-A1 | Process for producing ether compound | AGL, ARL1, CYP2C8 | LMNA 3226/4885 |
| US-20040181097-A1 | Process for producing ether compound | CYP2E1, ARL1, MRPL21 | LMNA 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.